Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without Continuous Renal Replacement Therapy.

Next Previous
X
Search
Trial Profile

An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without Continuous Renal Replacement Therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Gram-negative infections
  • Focus Pharmacokinetics
  • Acronyms CT-PK

    • Most Recent Events

    • 17 Aug 2019 Status changed from recruiting to completed.
    • 29 Jul 2019 Results evaluating population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal impairment and assess adequacy of recommended dosing regimenspublished in the Antimicrobial Agents and Chemotherapy
    • 27 Aug 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top